Cost and utility in immunocompromised subjects who developed herpes zoster during the randomized V212 inactivated varicella-zoster vaccine (ZVIN) trial-Reference-Cited by-同舟云学术

Cost and utility in immunocompromised subjects who developed herpes zoster during the randomized V212 inactivated varicella-zoster vaccine (ZVIN) trial

Published:2019-11-18 Issue:6 Volume:20 Page:613-621
ISSN:1473-7167
Container-title:Expert Review of Pharmacoeconomics & Outcomes Research
language:en
Short-container-title:Expert Review of Pharmacoeconomics & Outcomes Research

Author:

Eriksson Jennifer¹^ORCID,Hunger Matthias²,Bourhis François³,Thorén Robyn¹,Popmihajlov Zoran⁴,Finelli Lynn⁵,Jiang Yiling⁶

Affiliation:

1. Real-World Evidence Strategy & Analytics, ICON plc, Stockholm, Sweden

2. Real-World Evidence Strategy & Analytics, ICON plc, Munich, Germany

3. Global HTA, Health Economics, Reimbursement and Outcomes, ICON plc, Paris, France

4. Clinical Research, Merck & Co., Inc, Kenilworth, NJ, USA

5. Center for Observational and Real-world Evidence,L Merck & Co., Inc Kenilworth, NJ, UK

6. Center for Observational and Real-world Evidence, Merck Sharp & Dohme Ltd, Hoddesdon, UK

Funder

Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Health Policy,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737167.2020.1693267

Reference44 articles.

1. Herpes zoster and postherpetic neuralgia

2. Incidence of herpes zoster in patients with altered immune function

3. Burden of herpes zoster in 16 selected immunocompromised populations in England: a cohort study in the Clinical Practice Research Datalink 2000–2012

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-Effectiveness of Recombinant Zoster Vaccine for the Prevention of Herpes Zoster in Hematopoietic Stem Cell Transplant Recipients and Other Immunocompromised Adults in the United States;PharmacoEconomics - Open;2023-11